Sangart, a global biopharmaceutical company, has raised more than $50 million in a recent financing round, according to Bio SmartBrief. With the funds, the company will develop two new drug candidates, MP4OX and MP4CO.

MP4OX is intended to prevent tissue damage caused by low blood oxygen levels, and MP4CO is designed to prevent blood vessel blockage in patients with sickle cell disease.